1. Home
  2. CTNM vs NBP Comparison

CTNM vs NBP Comparison

Compare CTNM & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$11.44

Market Cap

416.1M

Sector

N/A

ML Signal

HOLD

NBP

NovaBridge Biosciences American Depositary Shares

N/A

Current Price

$3.98

Market Cap

370.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTNM
NBP
Founded
2009
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.1M
370.8M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
CTNM
NBP
Price
$11.44
$3.98
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
260.9K
500.0K
Earning Date
10-30-2025
02-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.35
$0.60
52 Week High
$15.25
$6.79

Technical Indicators

Market Signals
Indicator
CTNM
NBP
Relative Strength Index (RSI) 46.77 N/A
Support Level $11.66 N/A
Resistance Level $12.80 N/A
Average True Range (ATR) 0.69 0.00
MACD -0.07 0.00
Stochastic Oscillator 6.55 0.00

Price Performance

Historical Comparison
CTNM
NBP

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: